Vir Biotechnology Inc (VIR)
Interest coverage
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -552,122 | -570,044 | -540,001 | -619,694 | -685,157 | -698,879 | -319,238 | -334,584 | 821,120 | 1,519,747 | 1,273,772 | 1,559,261 | 388,851 | -264,610 | -297,342 | -384,488 | -297,454 | -253,504 | -213,569 | -220,593 |
Interest expense (ttm) | US$ in thousands | 0 | 239 | 239 | 239 | 478 | 9,959 | 19,291 | 39,180 | 39,329 | 29,609 | 20,277 | 388 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest coverage | — | -2,385.12 | -2,259.42 | -2,592.86 | -1,433.38 | -70.18 | -16.55 | -8.54 | 20.88 | 51.33 | 62.82 | 4,018.71 | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $-552,122K ÷ $0K
= —
Interest coverage ratio measures a company's ability to pay its interest expenses on outstanding debt. A higher ratio indicates that the company is more capable of meeting its interest obligations.
For Vir Biotechnology Inc, the interest coverage ratio was not available (denoted by "—") for the periods up to December 31, 2021. Starting from March 31, 2022, the interest coverage ratio was extremely high at 4,018.71, suggesting a strong ability to cover interest payments.
However, the ratio dropped significantly in the following quarters, indicating a decline in the company's ability to cover its interest expenses. The ratio turned negative in the periods from March 31, 2023, to December 31, 2024, which implies that the company's earnings were not sufficient to cover its interest costs during those periods.
The negative interest coverage ratios from March 31, 2023, to December 31, 2024, raise concerns about Vir Biotechnology Inc's financial stability and ability to meet its debt obligations solely through operating income. Further investigation into the company's financial health and debt management strategies may be necessary to understand the reasons behind the negative ratios and assess the risks associated with its debt levels.
Peer comparison
Dec 31, 2024